Last reviewed · How we verify
Intravenous immune globulin G
Intravenous immune globulin G (IVIG) provides passive immunity by delivering pooled immunoglobulin G antibodies from multiple donors to boost immune function and modulate inflammatory responses.
Intravenous immune globulin G (IVIG) provides passive immunity by delivering pooled immunoglobulin G antibodies from multiple donors to boost immune function and modulate inflammatory responses. Used for Primary immunodeficiency syndromes, Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV), Idiopathic thrombocytopenic purpura (ITP).
At a glance
| Generic name | Intravenous immune globulin G |
|---|---|
| Also known as | Privigen, IVIG |
| Sponsor | Rutgers, The State University of New Jersey |
| Drug class | Immunoglobulin replacement therapy / Immunomodulator |
| Target | Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | FDA-approved |
Mechanism of action
IVIG is a blood product containing polyclonal IgG antibodies collected from thousands of healthy donors. It works through multiple mechanisms: providing opsonizing antibodies against pathogens, blocking pathogenic autoantibodies, modulating complement activation, and regulating T and B cell function. It is used both for immunodeficiency replacement and as an immunomodulatory agent in autoimmune and inflammatory conditions.
Approved indications
- Primary immunodeficiency syndromes
- Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV)
- Idiopathic thrombocytopenic purpura (ITP)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Multifocal motor neuropathy
- Kawasaki disease
- Post-transfusion purpura
- Autoimmune hemolytic anemia
Common side effects
- Headache
- Fever
- Chills
- Myalgia
- Nausea
- Infusion site reactions
- Aseptic meningitis
- Thromboembolism
- Acute kidney injury
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (PHASE2)
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (PHASE1, PHASE2)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: